Rapid, accurate diagnosis
Cancer is an extremely complex and heterogenous disease which requires an accurate, early molecular and histopathological diagnosis in order to select the right treatment and thereby maximize efficacy and survival.
Our comprehensive and highly sensitive and specific range of tests can detect genetic alterations that drive tumor growth in all types of cancer. We are highly experienced in characterizing mechanisms of action of targeted therapies, particularly against epidermal growth factor receptor (EGFR), as well as other tyrosine kinase inhibitors.
Mutation analysis in tumor tissue and blood
Gene amplification and translocation testing
Our Molecular Oncology Laboratory is fully staffed by a team of highly experienced molecular biologists and pathologists and equipped with state-of-the-art technology. Our streamlined sample reception and processing systems, and proprietary data management software ensure efficient sample handling and communication with referring doctors and corporate clients.
We were the first laboratory to be accredited for analysis of EGFR mutations (exon 19, 20 (T790M) and 21), KRAS (exon 12-13) and BRAF (V600E) in tissue samples (laboratory accreditation nº750 / LE15156 Annex 7).
We offer an 8 working day turnaround on samples received and are able to process formalin-fixed paraffin-embedded tumor tissue, fresh frozen samples, serum, plasma, platelets, and cytologies.
Non-invasive 'liquid biopsy'
For certain cancers, we have developed highly sensitive and specific diagnostic tests using alternative biosources such as blood. This overcomes the challenges associated with obtaining sufficient tumor material for genetic analyses and makes serial treatment monitoring and early detection of therapy resistance a reality in personalized cancer treatment. We are one of the leading European providers in the field of liquid biopsies and the first pharmacogenomics laboratory in Spain to be accredited, by the National Accreditation Body (ENAC), ISO 15189, to perform genetic testing for cancer patients in liquid biopsy (serum/plasma) samples (EGFR mutations, exon 19, 20 [T790M] and 21; KRAS, exon 12-13; BRAF V600E) (nº750 / LE15156 Annex 7).
We perform pathological evaluation of tumors via bright field to confirm diagnoses. Our highly accurate microdissection equipment enables dissection of specific cells, ensuring maximum efficiency in subsequent tests.
In addition to our standard pathology services, we offer a wide range of FISH assays for determination of predictive biomarkers, and are experienced in immunohistochemistry (IHC) both for diagnostic and research purposes. We are also highly experienced in setting up new antibodies and probes upon request by our clients.
Our Pathology unit is led by Dr Santiago Ramon y Cajal. A leader in the field of pathology research, Dr Ramon y Cajal has focused on the identification of new therapeutic targets in cell signaling pathways and has received numerous awards in recognition of his work.
To request a copy of our Test Catalogue, place a request, inquire about any tests not included in the Catalogue, or for any other queries: Contact us. Please note all tests must be requested by a medical professional.